These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 36169178)

  • 21. Metformin treatment reduces temozolomide resistance of glioblastoma cells.
    Yang SH; Li S; Lu G; Xue H; Kim DH; Zhu JJ; Liu Y
    Oncotarget; 2016 Nov; 7(48):78787-78803. PubMed ID: 27791206
    [TBL] [Abstract][Full Text] [Related]  

  • 22. MicroRNA-128-3p Enhances the Chemosensitivity of Temozolomide in Glioblastoma by Targeting c-Met and EMT.
    Zhao C; Guo R; Guan F; Ma S; Li M; Wu J; Liu X; Li H; Yang B
    Sci Rep; 2020 Jun; 10(1):9471. PubMed ID: 32528036
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Recycling drug screen repurposes hydroxyurea as a sensitizer of glioblastomas to temozolomide targeting de novo DNA synthesis, irrespective of molecular subtype.
    Teng J; Hejazi S; Hiddingh L; Carvalho L; de Gooijer MC; Wakimoto H; Barazas M; Tannous M; Chi AS; Noske DP; Wesseling P; Wurdinger T; Batchelor TT; Tannous BA
    Neuro Oncol; 2018 Apr; 20(5):642-654. PubMed ID: 29099956
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Characterization and comparison of human glioblastoma models.
    Schulz JA; Rodgers LT; Kryscio RJ; Hartz AMS; Bauer B
    BMC Cancer; 2022 Aug; 22(1):844. PubMed ID: 35922758
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Dual mTORC1/2 blockade inhibits glioblastoma brain tumor initiating cells in vitro and in vivo and synergizes with temozolomide to increase orthotopic xenograft survival.
    Luchman HA; Stechishin OD; Nguyen SA; Lun XQ; Cairncross JG; Weiss S
    Clin Cancer Res; 2014 Nov; 20(22):5756-67. PubMed ID: 25316808
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The DNA repair protein ALKBH2 mediates temozolomide resistance in human glioblastoma cells.
    Johannessen TC; Prestegarden L; Grudic A; Hegi ME; Tysnes BB; Bjerkvig R
    Neuro Oncol; 2013 Mar; 15(3):269-78. PubMed ID: 23258843
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Silencing of ZFP36L2 increases sensitivity to temozolomide through G2/M cell cycle arrest and BAX mediated apoptosis in GBM cells.
    Che Mat MF; Mohamad Hanif EA; Abdul Murad NA; Ibrahim K; Harun R; Jamal R
    Mol Biol Rep; 2021 Feb; 48(2):1493-1503. PubMed ID: 33590411
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Encapsulation of Temozolomide in a Calixarene Nanocapsule Improves Its Stability and Enhances Its Therapeutic Efficacy against Glioblastoma.
    Renziehausen A; Tsiailanis AD; Perryman R; Stylos EK; Chatzigiannis C; O'Neill K; Crook T; Tzakos AG; Syed N
    Mol Cancer Ther; 2019 Sep; 18(9):1497-1505. PubMed ID: 31213505
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The TNF receptor family member Fn14 is highly expressed in recurrent glioblastoma and in GBM patient-derived xenografts with acquired temozolomide resistance.
    Hersh DS; Harder BG; Roos A; Peng S; Heath JE; Legesse T; Kim AJ; Woodworth GF; Tran NL; Winkles JA
    Neuro Oncol; 2018 Sep; 20(10):1321-1330. PubMed ID: 29897522
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Anti-SEMA3A Antibody: A Novel Therapeutic Agent to Suppress Glioblastoma Tumor Growth.
    Lee J; Shin YJ; Lee K; Cho HJ; Sa JK; Lee SY; Kim SH; Lee J; Yoon Y; Nam DH
    Cancer Res Treat; 2018 Jul; 50(3):1009-1022. PubMed ID: 29129044
    [TBL] [Abstract][Full Text] [Related]  

  • 31. T-Type Ca
    Visa A; Sallán MC; Maiques O; Alza L; Talavera E; López-Ortega R; Santacana M; Herreros J; Cantí C
    Cancer Res; 2019 Apr; 79(8):1857-1868. PubMed ID: 30755443
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The telomerase antagonist, imetelstat, efficiently targets glioblastoma tumor-initiating cells leading to decreased proliferation and tumor growth.
    Marian CO; Cho SK; McEllin BM; Maher EA; Hatanpaa KJ; Madden CJ; Mickey BE; Wright WE; Shay JW; Bachoo RM
    Clin Cancer Res; 2010 Jan; 16(1):154-63. PubMed ID: 20048334
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Epigenetic preconditioning with decitabine sensitizes glioblastoma to temozolomide via induction of MLH1.
    Gallitto M; Cheng He R; Inocencio JF; Wang H; Zhang Y; Deikus G; Wasserman I; Strahl M; Smith M; Sebra R; Yong RL
    J Neurooncol; 2020 May; 147(3):557-566. PubMed ID: 32193690
    [TBL] [Abstract][Full Text] [Related]  

  • 34. IKBKE enhances TMZ-chemoresistance through upregulation of MGMT expression in glioblastoma.
    Guo G; Sun Y; Hong R; Xiong J; Lu Y; Liu Y; Lu J; Zhang Z; Guo C; Nan Y; Huang Q
    Clin Transl Oncol; 2020 Aug; 22(8):1252-1262. PubMed ID: 31865606
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Differential expression of miR16 in glioblastoma and glioblastoma stem cells: their correlation with proliferation, differentiation, metastasis and prognosis.
    Tian R; Wang J; Yan H; Wu J; Xu Q; Zhan X; Gui Z; Ding M; He J
    Oncogene; 2017 Oct; 36(42):5861-5873. PubMed ID: 28628119
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Novel Targeting of Transcription and Metabolism in Glioblastoma.
    Su YT; Chen R; Wang H; Song H; Zhang Q; Chen LY; Lappin H; Vasconcelos G; Lita A; Maric D; Li A; Celiku O; Zhang W; Meetze K; Estok T; Larion M; Abu-Asab M; Zhuang Z; Yang C; Gilbert MR; Wu J
    Clin Cancer Res; 2018 Mar; 24(5):1124-1137. PubMed ID: 29254993
    [No Abstract]   [Full Text] [Related]  

  • 37. Combination therapy in a xenograft model of glioblastoma: enhancement of the antitumor activity of temozolomide by an MDM2 antagonist.
    Wang H; Cai S; Bailey BJ; Reza Saadatzadeh M; Ding J; Tonsing-Carter E; Georgiadis TM; Zachary Gunter T; Long EC; Minto RE; Gordon KR; Sen SE; Cai W; Eitel JA; Waning DL; Bringman LR; Wells CD; Murray ME; Sarkaria JN; Gelbert LM; Jones DR; Cohen-Gadol AA; Mayo LD; Shannon HE; Pollok KE
    J Neurosurg; 2017 Feb; 126(2):446-459. PubMed ID: 27177180
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Human glioblastoma multiforme: p53 reactivation by a novel MDM2 inhibitor.
    Costa B; Bendinelli S; Gabelloni P; Da Pozzo E; Daniele S; Scatena F; Vanacore R; Campiglia P; Bertamino A; Gomez-Monterrey I; Sorriento D; Del Giudice C; Iaccarino G; Novellino E; Martini C
    PLoS One; 2013; 8(8):e72281. PubMed ID: 23977270
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Temozolomide-induced increase of tumorigenicity can be diminished by targeting of mitochondria in in vitro models of patient individual glioblastoma.
    William D; Walther M; Schneider B; Linnebacher M; Classen CF
    PLoS One; 2018; 13(1):e0191511. PubMed ID: 29352318
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Study on Therapeutic Action and Mechanism of TMZ Combined with RITA Against Glioblastoma.
    Wu Q; Cao Z; Xiao W; Zhu L; Xie Q; Li L; Zhang B; Zhao W
    Cell Physiol Biochem; 2018; 51(6):2536-2546. PubMed ID: 30562758
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.